Medifast experienced a significant decline in its third-quarter 2025 financial results, with revenue decreasing by 36.2% to $89.4 million and reporting a net loss of $2.3 million. This downturn was largely attributed to a 35.0% decrease in active earning OPTAVIA coaches, impacted by the growing acceptance of GLP-1 medications for weight loss. Despite the challenges, the company maintains a strong balance sheet with $173.5 million in cash and no debt, and is strategically shifting its focus towards metabolic health.
Revenue for Q3 2025 decreased by 36.2% to $89.4 million compared to $140.2 million in Q3 2024.
The company reported a net loss of $2.3 million, or $0.21 loss per diluted share, in Q3 2025, a decline from a net income of $1.1 million in Q3 2024.
The number of active earning OPTAVIA coaches decreased by 35.0% to 19,500, down from 30,000 in the prior year.
Medifast maintains a strong balance sheet with $173.5 million in cash, cash equivalents, and investment securities, and no debt.
Medifast expects fourth quarter 2025 revenue to be between $65 million and $80 million, with a diluted loss per share ranging from $0.70 to $1.25.
Analyze how earnings announcements historically affect stock price performance